回顾性分析儿科肿瘤人群中泊沙康唑混悬液的给药方案：单中心经验。
Retrospective Analysis of Posaconazole Suspension Dosing Strategies in a Pediatric Oncology Population: Single-Center Experience.
机构信息
Departments of1Pharmacy.
Epidemiology and Biostatistics.
出版信息
J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):e149-e151. doi: 10.1093/jpids/pix058.
Abstract
Limited data on optimal posaconazole dosing strategies for pediatric patients exist. In this study, we found that the median initial dose in patients who achieved a posaconazole plasma concentration of 0.7 μg/mL was 22.8 mg/kg per day whereas the median initial dose in those who did not reach the target concentration was 15.8 mg/kg per day; this result suggests that higher initial doses might be warranted.
摘要
关于儿童患者最佳泊沙康唑给药方案的数据有限。本研究发现，达到泊沙康唑血药浓度 0.7μg/ml 的患者的中位起始剂量为 22.8mg/kg/天，而未达到目标浓度的患者的中位起始剂量为 15.8mg/kg/天；这表明较高的初始剂量可能是必要的。
相似文献
1
Retrospective Analysis of Posaconazole Suspension Dosing Strategies in a Pediatric Oncology Population: Single-Center Experience.回顾性分析儿科肿瘤人群中泊沙康唑混悬液的给药方案：单中心经验。
J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):e149-e151. doi: 10.1093/jpids/pix058.
2
Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed-release tablet and intravenous posaconazole.延迟释放片和静脉用泊沙康唑治疗的儿童、青少年和青年患者中实现泊沙康唑治疗血药浓度所需的初始泊沙康唑剂量。
Pediatr Transplant. 2020 Sep;24(6):e13777. doi: 10.1111/petr.13777. Epub 2020 Jul 8.
3
Clinical effectiveness of early posaconazole suspension pre-emptive therapy in lung transplant recipients: The Alfred's experience.肺移植受者中早期泊沙康唑混悬液抢先治疗的临床疗效：Alfred 医院的经验。
J Antimicrob Chemother. 2017 Jul 1;72(7):2089-2092. doi: 10.1093/jac/dkx085.
4
Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.泊沙康唑治疗药物监测在癌症患儿和青年患者中的应用。
Ann Pharmacother. 2013 Jul-Aug;47(7-8):976-83. doi: 10.1345/aph.1R775. Epub 2013 Jun 4.
5
Evaluation of Intravenous Posaconazole Dosing and Pharmacokinetic Target Attainment in Pediatric Patients.评价儿科患者静脉用泊沙康唑的给药剂量和药代动力学目标达成情况。
J Pediatric Infect Dis Soc. 2019 Sep 25;8(4):365-367. doi: 10.1093/jpids/piy094.
6
Therapeutic Drug Monitoring and Dose Adjustment of Posaconazole Oral Suspension in Adults With Acute Myeloid Leukemia.泊沙康唑口服混悬液在成人急性髓系白血病中的治疗药物监测与剂量调整
Ther Drug Monit. 2015 Aug;37(4):508-11. doi: 10.1097/FTD.0000000000000175.
7
Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents.免疫功能低下的儿童和青少年服用泊沙康唑延迟释放片后的血浆暴露情况。
J Antimicrob Chemother. 2019 Dec 1;74(12):3573-3578. doi: 10.1093/jac/dkz359.
8
[Use of posaconazole in children: Experience in a tertiary pediatric hospital].泊沙康唑在儿童中的应用：一家三级儿科医院的经验
Arch Argent Pediatr. 2018 Jun 1;116(3):e451-e454. doi: 10.5546/aap.2018.e451.
9
Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review.13岁以下儿童泊沙康唑口服混悬液的治疗药物监测：一项回顾性分析与文献综述
J Clin Pharm Ther. 2017 Feb;42(1):75-79. doi: 10.1111/jcpt.12483. Epub 2016 Dec 16.
10
Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.儿科血液肿瘤患者的泊沙康唑口服剂量和血药浓度。
Eur J Haematol. 2018 Mar;100(3):315-322. doi: 10.1111/ejh.13017. Epub 2018 Jan 10.
引用本文的文献
1
Relationship between posaconazole concentrations and clinical outcomes in paediatric cancer and haematopoietic stem cell transplant recipients.泊沙康唑浓度与儿科癌症及造血干细胞移植受者临床结局之间的关系。
J Antimicrob Chemother. 2025 Apr 2;80(4):897-907. doi: 10.1093/jac/dkae473.
2
Therapeutic drug monitoring of posaconazole oral suspension in paediatric hematology patients under 13 years of age.13岁以下儿科血液学患者泊沙康唑口服混悬液的治疗药物监测
Transl Pediatr. 2025 Jan 24;14(1):4-13. doi: 10.21037/tp-24-400. Epub 2025 Jan 21.
3
Efficacy and Safety Assessment of Antifungal Prophylaxis with Posaconazole Using Therapeutic Drug Monitoring in Pediatric Patients with Oncohematological Disorders-A Single-Centre Study.泊沙康唑预防性抗真菌治疗对肿瘤血液系统疾病患儿疗效及安全性评估的治疗药物监测——一项单中心研究
J Fungi (Basel). 2025 Jan 6;11(1):38. doi: 10.3390/jof11010038.
4
Dose Optimisation of Posaconazole and Therapeutic Drug Monitoring in Pediatric Patients.泊沙康唑在儿科患者中的剂量优化及治疗药物监测
Front Pharmacol. 2022 Apr 19;13:833303. doi: 10.3389/fphar.2022.833303. eCollection 2022.
5
Evaluation of Posaconazole Dosing in Children and Young Adults: A Single-Center Review.儿童和青年成人泊沙康唑给药剂量的评估：一项单中心回顾
J Pediatr Pharmacol Ther. 2021;26(8):834-840. doi: 10.5863/1551-6776-26.8.834. Epub 2021 Nov 10.
本文引用的文献
1
Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.泊沙康唑治疗药物监测在癌症患儿和青年患者中的应用。
Ann Pharmacother. 2013 Jul-Aug;47(7-8):976-83. doi: 10.1345/aph.1R775. Epub 2013 Jun 4.
2
Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.分析泊沙康唑作为 12 岁以下异基因造血干细胞移植后患儿的口服抗真菌预防用药。
BMC Infect Dis. 2012 Oct 19;12:263. doi: 10.1186/1471-2334-12-263.
3
Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.泊沙康唑暴露-反应关系：评估治疗药物监测的效用。
Antimicrob Agents Chemother. 2012 Jun;56(6):2806-13. doi: 10.1128/AAC.05900-11. Epub 2012 Mar 5.
4
Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma.泊沙康唑用于预防侵袭性真菌感染的暴露-反应：评估是否需要根据血浆药物浓度调整剂量。
Clin Pharmacol Ther. 2010 Jul;88(1):115-9. doi: 10.1038/clpt.2010.64. Epub 2010 May 26.
5
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.欧洲癌症研究与治疗组织/侵袭性真菌感染合作组和美国国立过敏与传染病研究所真菌病研究组（EORTC/MSG）共识组对侵袭性真菌病的修订定义。
Clin Infect Dis. 2008 Jun 15;46(12):1813-21. doi: 10.1086/588660.
6
Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.口服泊沙康唑在患有移植物抗宿主病的异基因造血干细胞移植受者中的药代动力学。
Pharmacotherapy. 2007 Dec;27(12):1627-36. doi: 10.1592/phco.27.12.1627.
7
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.泊沙康唑或氟康唑用于严重移植物抗宿主病的预防。
N Engl J Med. 2007 Jan 25;356(4):335-47. doi: 10.1056/NEJMoa061098.
8
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.泊沙康唑治疗对传统疗法难治或不耐受的侵袭性曲霉病患者：一项外部对照试验。
Clin Infect Dis. 2007 Jan 1;44(1):2-12. doi: 10.1086/508774. Epub 2006 Nov 28.
Zotero 插件